Latest Insider Transactions at Lyell Immunopharma, Inc. (LYEL)
This section provides a real-time view of insider transactions for Lyell Immunopharma, Inc. (LYEL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Lyell Immunopharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Lyell Immunopharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 09
2024
|
Matthew Lang Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Feb 09
2024
|
Gary K. Lee Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+43.15%
|
-
|
|
Feb 09
2024
|
Stephen J. Hill Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+44.98%
|
-
|
|
Feb 09
2024
|
Lynn Seely President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
-
|
|
Feb 09
2024
|
Charles W. Newton Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+45.08%
|
-
|
|
Aug 15
2023
|
Richard Klausner |
SELL
Open market or private sale
|
Indirect |
58,020
-5.87%
|
$116,040
$2.28 P/Share
|
|
Sep 23
2022
|
Richard Klausner |
SELL
Open market or private sale
|
Indirect |
11,100
-1.11%
|
$66,600
$6.4 P/Share
|
|
Sep 08
2022
|
Hans Edgar Bishop |
BUY
Exercise of conversion of derivative security
|
Direct |
145,380
+3.01%
|
$0
$0.1 P/Share
|
|
Feb 23
2022
|
Hans Edgar Bishop |
BUY
Exercise of conversion of derivative security
|
Direct |
993,428
+17.95%
|
$0
$0.1 P/Share
|
|
Dec 14
2021
|
Cathy Friedman |
BUY
Other acquisition or disposition
|
Indirect |
218,722
+48.06%
|
-
|
|
Dec 14
2021
|
Cathy Friedman |
SELL
Other acquisition or disposition
|
Indirect |
3,765,842
-100.0%
|
-
|
|
Jun 21
2021
|
Cathy Friedman |
BUY
Open market or private purchase
|
Indirect |
17,648
+50.0%
|
$300,016
$17.0 P/Share
|
|
Jun 21
2021
|
Cathy Friedman |
BUY
Conversion of derivative security
|
Indirect |
3,765,842
+50.0%
|
-
|
|
Jun 21
2021
|
Hans Edgar Bishop |
BUY
Conversion of derivative security
|
Direct |
546,806
+13.36%
|
-
|
|
Jun 21
2021
|
Richard Klausner |
BUY
Conversion of derivative security
|
Indirect |
3,765,842
+50.0%
|
-
|
|
Jun 21
2021
|
Robert Nelsen |
BUY
Conversion of derivative security
|
Indirect |
36,412,716
+50.0%
|
-
|
|
Jun 21
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
36,412,716
+50.0%
|
-
|
|
Jun 21
2021
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
30,253,189
+50.0%
|
-
|